Anthracycline-induced phospholipase A2 inhibition

Cardiovascular Toxicology

Volumn 7, Issue 2, 2007, Pages 86-91

  Swift, Luther ^a   McHowat, Jane ^b   Sarvazyan, Narine ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anthracyclines; Cardiomyocytes; Cardiomyopathy; Phospholipase A2; Phospholipids

Indexed keywords

ANTHRACYCLINE; COPPER ZINC SUPEROXIDE DISMUTASE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; PHOSPHOLIPASE A2;

CARDIOMYOPATHY; CARDIOTOXICITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; DOXORUBICIN; ENZYME INHIBITORS; HEART DISEASES; HUMANS; OXIDATIVE STRESS; PHOSPHOLIPASES A; PHOSPHOLIPIDS;

EID: 34548324275     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-007-0012-6     Document Type: Conference Paper

References (27)

1. McHowat, J., Swift, L. M., Arutunyan, A., & Sarvazyan, N. (2001). Clinical concentrations of doxorubicin inhibit activity of myocardial membrane-associated, calcium-independent phospholipase A(2). Cancer Research, 61, 4024-4029.
2. McHowat, J., Swift, L. M., & Sarvazyan, N. (2001). Oxidant-induced inhibition of myocardial calcium-independent phospholipase A2. Cardiovascular Toxicology, 1, 309-316.
3. Swift, L., McHowat, J., & Sarvazyan, N. (2003). Inhibition of Membrane-associated Calcium-independent Phospholipase A2 as a Potential Culprit of Anthracycline Cardiotoxicity. Cancer Research, 63, 5992-5998.
4. McHowat, J., Swift, L. M., Crown, K. N., & Sarvazyan, N. A. (2004). Changes in phospholipid content and myocardial calcium-independent phospholipase A2 activity during chronic anthracycline administration. The Journal of Pharmacology and Experimental Therapeutics, 311, 736-741.
5. Sarvazyan, N. A., Askari, A., & Huang, W. H. (1995). Effects of doxorubicin on cardiomyocytes with reduced level of superoxide dismutase. Life Science, 57, 1003-1010.
6. Sarvazyan, N. (1996). Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. The American Journal of Physiology, 271, H2079-H2085.
7. Swift, L. M., & Sarvazyan, N. (2000). Localization of dichloro-fluorescin in cardiac myocytes: implications for assessment of oxidative stress. American Journal Of Physiology. Heart and Circulatory Physiology, 278, H982-H990.
8. Weiss, RB (1992). The anthracyclines: will we ever find a better doxorubicin? Seminars in Oncology, 19, 670-686.
9. Weiss, R. B., Sarosy, G., Clagett-Carr, K., Russo, M., & Leyland-Jones, B. (1986). Anthracycline analogs: the past, present, and future. Cancer Chemotherapy and Pharmacology, 18, 185-197.
10. Czarnecki, C. M. (1984). Animal models of drug-induced cardiomyopathy. Comparative Biochemistry And Physiology C, 79, 9-14.
11. Della Torre, P., Podesta, A., Pinciroli, G., Iatropoulos, M. J., & Mazue, G. (1996). Long-lasting effect of dexrazoxane against anthracycline cardiotoxicity in rats. Toxicologic Pathology, 24, 398-402.
12. McHowat, J., Tappia, P. S., Liu, S. -Y., McCrory, R., & Panagia, V. (2001). Redistribution and abnormal activity of phospholipase A2 isoenzymes in postinfarct congestive heart failure. American Journal Of Physiology. Cell Physiology, 280, C573-C580.
13. Sevanian, A. (1988). Lipid damage and repair. In K. J Davies (Ed.) Oxidative damage and repair. New York: Pergamon Press, pp 543-549.
14. dMcHowat, J., & Creer, M. H. (1998). Calcium-independent phospholipase A2 in isolated rabbit ventricular myocytes. Lipids, 33, 1203-1212.
15. McHowat, J., & Creer, M. H. (2000). Selective plasmalogen substrate utilization by thrombin-stimulated Ca(2+)-independent PLA(2) in cardiomyocytes. American Journal Of Physiology. Heart and Circulatory Physiology, 278, H1933-H1940.
16. Hazen, S. L., Zupan, L. A., Weiss, R. H., Getman, D. P., & Gross, R. W. (1991). Suicide inhibition of canine myocardial cytosolic calcium-independent phospholipase A2. Mechanism-based discrimination between calcium-dependent and -independent phospholipases A2. The Journal of Biological Chemistry, 266, 7227-7232.
17. Thayer, W. S. (1984). Serum lipid peroxides in rats treated chronically with adriamycin. Biochemical Pharmacology, 33, 2259-2263.
18. Malisza, K. L., McIntosh, A. R., Sveinson, S. E., & Hasinoff, B. B. (1996). Semiquinone free radical formation by daunorubicin aglycone incorporated into the cellular membranes of intact Chinese hamster ovary cells. Free Radical Research, 24, 9-18.
19. Thomas, J. P., Maiorino, M., Ursini, F., & Girotti, A. W. (1990). Protective action of phospholipid hydroperoxide glutathione peroxidase against membrane-damaging lipid peroxidation. In situ reduction of phospholipid and cholesterol hydroperoxides. The Journal of Biological Chemistry, 265, 454-461.
20. Bermano, G., Nicol, F., & Dyer, J. A. et al. (1995). Tissue-specific regulation of selenoenzyme gene expression during selenium deficiency in rats. Biochemistry Journal, 311, 425-430.
21. Jotti, A., Maiorino, M., Paracchini, L., Piccinini, F., & Ursini, F. (1994). Protective effect of dietary selenium supplementation on delayed cardiotoxicity of adriamycin in rat: is PHGPX but not GPX involved? Free Radical Biology and Medicine, 16, 283-288.
22. Boucek, R. J. Jr., Miracle, A., Anderson, M., Engelman, R., Atkinson, J., & Dodd, D. A. (1999). Persistent effects of doxorubicin on cardiac gene expression. Journal of Molecular and Cellular Cardiology, 31, 1435-1446.
23. Pessah, I. N., Schiedt, M. J., Shalaby, M. A., Mack, M., & Giri, S. N. (1992). Etiology of sarcoplasmic reticulum calcium release channel lesions in doxorubicin-induced cardiomyopathy. Toxicology, 72, 189-206.
24. Bers, D. M. (2002). Calcium and cardiac rhythms: physiological and pathophysiological. Circulation Research, 90, 14-17.
25. Liu, S. Y., Tappia, P. S., Dai, J., Williams, S. A., & Panagia, V. (1998). Phospholipase A2-mediated activation of phospholipase D in rat heart sarcolemma. Journal of Molecular and Cellular Cardiology, 30, 1203-1214.
26. Xu, Y. J., Panagia, V., Shao, Q., Wang, X., & Dhalla, N. S. (1996). Phosphatidic acid increases intracellular free Ca2+ and cardiac contractile force. American Journal of Physiology, 271, H651-H659.
27. Minotti, G., Mancuso, C., & Frustaci, A. et al. (1996). Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity. The Journal of Clinical Investigation, 98, 650-661.